Market Value160,362,000
Total Holdings52
File Date2016-05-27
Original Filing (Click here)

All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings. These reports are called 13F reports. However, the filings are required the following quarter from the reporting period, which means that by the time the filing is made (and we see them), the information could be five months old.

For funds with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover, the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions are identified in the table. However, they are not required to report short positions.

Click the link icon to see the full transaction history.

Upgrade to unlock premium data and export to Excel .

Security Imputed
Share Price
Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
(USD x1000)
Current Value
(USD x1000)
Change
(Percent)
GERN / Geron Corporation
NBRV / Nabriva Therapeutics Plc
FGEN / FibroGen, Inc.
AGRX / Agile Therapeutics, Inc.
TRIL / Trillium Therapeutics Inc
GNMX / Aevi Genomic Medicine, Inc.
IL0011177958 / Intec Pharma Ltd
AVDL / Avadel Pharmaceuticals plc
FOMX / Foamix Pharmaceuticals Ltd.
PDSB / PDS Biotechnology Corporation
/ Achaogen Inc
US16706W1027 / Chiasma Inc
/ Immunomedics, Inc.
SUPN / Supernus Pharmaceuticals, Inc.
AGIO / Agios Pharmaceuticals, Inc.
CLLS / Cellectis S.A. - Depositary Receipt (Common Stock)
NBSE / NeuBase Therapeutics, Inc.
ALDR / Alder BioPharmaceuticals, Inc.
H03579101 / Auris Medical Holding Ltd
VTAE / Vitae Pharmaceuticals, Inc.
NDRM / NeuroDerm Ltd.
ACRS / Aclaris Therapeutics, Inc.
CORI / Corium International, Inc.
74365AAB7 / Protalix BioTherapeutics, Inc. Bonds 4.5% 9/15/18
AXGN / Axogen, Inc.
CYNA / Cynapsus Therapeutics Inc.
45780VAA0 / Inotek Pharmaceuticals Corporation Bond
RARE / Ultragenyx Pharmaceutical Inc.
LJPC / La Jolla Pharmaceutical Co.
EVOK / Evoke Pharma, Inc.
MDVN / Medivation, Inc.
AXDX / Accelerate Diagnostics, Inc.
TNXP / Tonix Pharmaceuticals Holding Corp.
RLYP / Relypsa, Inc.
MLNT / Melinta Therapeutics, Inc.
TENX / Tenax Therapeutics, Inc.
ALPN / Alpine Immune Sciences, Inc.
CMRX / Chimerix, Inc.
ADMS / Adamas Pharmaceuticals Inc
ASRT / Assertio Holdings, Inc.
XENE / Xenon Pharmaceuticals Inc.
ISEE / IVERIC bio Inc
HROW / Harrow, Inc.
ARIA / ARIAD Pharmaceuticals, Inc.
NKTR / Nektar Therapeutics
AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock)
PRTA / Prothena Corporation plc
MGNX / MacroGenics, Inc.
ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
ZGNX / Zogenix Inc
TVTX / Travere Therapeutics, Inc.
BLRX / BioLineRx Ltd. - Depositary Receipt (Common Stock)
CARA / Cara Therapeutics, Inc.
AVGR / Avinger, Inc.
SGMO / Sangamo Therapeutics, Inc.
BPMC / Blueprint Medicines Corporation
SAGE / Sage Therapeutics, Inc.
EGRX / Eagle Pharmaceuticals, Inc.
EGRX / Eagle Pharmaceuticals, Inc.
XOMA / XOMA Royalty Corporation
AFMD / Affimed N.V.
NBIX / Neurocrine Biosciences, Inc.
US00163U1060 / AMAG Pharmaceuticals, Inc.
TGTX / TG Therapeutics, Inc.
CDXS / Codexis, Inc.
TARA / Protara Therapeutics, Inc.